Citadel Advisors
RKDA icon

Citadel Advisors’s Arcadia Biosciences RKDA Stock Holding History

Citadel Advisors’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-323
Closed -$3.5K – 15390
2022
Q4 		$3.5K Sell
323
-2
-0.6% -$28 ﹤0.01% 14204
2022
Q3 		$7K Buy
+325
New +$11.1K ﹤0.01% 12327
2022
Q1 		– Sell
-435
Closed -$18K – 14425
2021
Q4 		$18K Sell
435
-591
-58% -$38.5K ﹤0.01% 13600
2021
Q3 		$85K Sell
1,026
-398
-28% -$37.3K ﹤0.01% 13022
2021
Q2 		$169K Buy
1,424
+506
+55% +$55.2K ﹤0.01% 12366
2021
Q1 		$101K Buy
918
+157
+21% +$19.3K ﹤0.01% 12469
2020
Q4 		$77K Buy
+761
New +$92.9K ﹤0.01% 10364

Other funds holding RKDA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's RKDA Position: Q1 2023 in Review

Citadel Advisors sold out of Arcadia Biosciences (RKDA) in Q1 2023, closing a stake of 4,536 shares — an estimated $49.2K sold.

Citadel Advisors first reported a position in RKDA in Q3 2016 and held it in 9 quarters. The position peaked at $77K in Q3 2019. 15 funds tracked by Wall St. Rank hold RKDA as of Q1 2023.

  • Citadel Advisors reported no remaining Arcadia Biosciences position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,536 Arcadia Biosciences shares in Q1 2023, an estimated $49.2K.
  • Citadel Advisors first reported a position in Arcadia Biosciences in Q3 2016 and held it in 9 quarters.
  • Citadel Advisors's Arcadia Biosciences position peaked at $77K in Q3 2019.
  • 15 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.